The key secondary end point of overall survival (OS) was met in the DREAMM-7 trial of belantamab mafodotin (Blenrep; GSK) for the treatment of patients with relapsed/refractory multiple myeloma (R/R ...

Xeltis recently announced that the FDA has granted Breakthrough Device designation for the company’s aXess vascular acce ...

Key Takeaways The S&P 500 added 0.4% on Tuesday, Nov. 19, as investors digested a strong report from a major retailer and ...

EndoTheia announced today that it completed the first-in-human clinical trial for its FlexStone basket, a steerable kidney ...

Approximately 16% of the global population, or about 890 million people, suffer from obesity. The World Health Organization ...

The FDA granted fast track designation to ALE.P02, an antibody-drug conjugate targeting Claudin-1 (CLDN1), for use in ...

The National Institutes of Health (NIH) has unveiled a new artificial intelligence (AI) algorithm designed to more ...

The World Institute of Kimchi(WIKIM) has announced that the regular consumption of kimchi, a traditional Korean fermented ...

A recent discussion with BDO's clinical trials editor and Audrey Davis of CSC, discussed strategies to increase clinical ...

Nine years as an ovarian cancer “lifer” yields these tips for surviving and thriving when there’s no end of treatment ahead.

Barbara O’Brien, MD, discusses the background behind the phase 2 TBCRC049 study investigating the combination of tucatinib, trastuzumab, and capecitabine for the treatment of patients with ...

A previous pilot study examining the company’s SJP-001 compound found it was able to cut hangover symptoms such as headaches, ...